CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

CVRx Inc.

In a report released today, William Plovanic from Canaccord Genuity reiterated a Buy rating on CVRx, with a price target of $11.00. According to Ti...

CVRx (CVRX) Gets a Buy from Canaccord Genuity

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CVRx (CVRX – Research Report) and Lifecore Biomedica...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CVRX	$8.45	+0.36%	154.81K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CVRX	$8.45	+0.4%	154.81K
3
4
5
6

CVRX

CVRX

Dividend Overview

Get CVRx Inc. Data in Excel

Get CVRx Inc. Data in Excel